Does failure of single hormone therapy delineate hormone refractoriness for prostate cancer?

Scandinavian Journal of Urology and Nephrology

Volumn 42, Issue 2, 2008, Pages 116-120

  Kotwal, Sanjeev ^a   Whelan, Peter ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Hormone refractoriness; Hormone therapy; Prognosis; Prostate cancer

Indexed keywords

ANTIANDROGEN; ESTROGEN; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REFRACTORY PERIOD; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 84936996595     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590701571548     Document Type: Article

References (19)

1. Huggins C, Hodges CV. The effect of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;43:209-12.
2. Collins WP, Mansfield MD, Alladina NS, Sommerville IF. Radioimmunoassay of plasma testosterone. J Steroid Biochem 1972;3:333-48.
3. Blackard CE, Doe RP, Mellinger GT, Byar DP. Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate. Cancer 1970;26:249-56.
4. The Veterans Administration Cooperative Urological Research Group. Carcinoma of prostate: treatment comparisons. J Urol 1967;98:516-22.
5. Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973;32:1126-30.
6. Bailar JC 3rd, Byar DP. Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo. Cancer 1970;26:257-61.
7. Clark P, Houghton L. Sub capsular orchidectomy for carcinoma of the prostate. Br J Urol 1977;49:419-25.
8. Tolis G, Mehta A, Comaru-Schally AM, Schally AV. Suppression of androgen production by D-tryptophan-6-luteinizing hormone-releasing hormone in man. J Clin Invest 1981;68:819-22.
9. Scherr DS, Pitts WR. The non steroidal effects of diethylstilbesterol: the rationale for androgen deprivation therapy without oestrogen deprivation in the treatment of prostate cancer. J Urol 2003;170:1703-8.
10. Bolla M, Gonsalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
11. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
12. Chang SS, Benson MC, Campbell SC, Crook J, Dreicer R, Evans CP, et al. Society of Urologic Oncology position statement redefining the management of hormone-refractory prostate carcinoma. Cancer 2005;103:11-21.
13. Newling D, Fossa SD, Andersson L, Abrahamsson PA, Aso Y, Eisenberger MA, et al. Assessment of hormone refractory prostate cancer. Urology 1997;49:46-53.
14. Gleave ME, Small EJ. Androgen deprivation therapy for prostate cancer. In: Caroll PR, Nelson WG, editors. Report to the nation on prostate cancer 2004. Elmwood Park, NJ: Medscape; 2004. p. 27-36.
15. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006;175:27-34.
16. Iversen P, Rasmussen F, Asmussen C, Christensen IJ, Eickhoff J, Klarskov P, et al. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group. J Urol 1997;57:929-34.
17. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
18. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisolone for advanced prostate cancer. N Engl J Med 2005;351:1502-12.
19. Petrylak DP, Tangen CM, Hussain MHA, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2005;351:1513-20.